Ofloxacin (ofloxacin)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Ofloxacin is a fluoroquinolone anti-infective agent.
USES: Ofloxacin is used to treat outer ear infections (swimmer's ear or ear canal infections) and middle ear infections. It works by stopping the growth of bacteria. This medication belongs to a class of drugs called quinolone antibiotics.
This medication treats only bacterial ear infections. It will not work for other types of ear infections. Using any antibiotic when it is not needed can cause it to not work for future infections.
Generic name: ofloxacin
Pronunciation: (oh-FLOX-a-sin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ofloxacin
Indications
The following indications are listed for Ofloxacin:
- Acute Pseudomonas Aeruginosa Otitis Externa
- Acute Staphylococcus Aureus Otitis Externa
- Acute Suppurative Otitis Media With Tympanostomy Tubes
- Chronic Tubotympanic Suppurative Otitis Media
- Otitis Externa
Also known as: Acute Otitis Externa Due To Pseudomonas Aeruginosa, Acute Otitis Externa Due To Staphylococcus Aureus, Acute Otitis Externa Due To Staphylococcus Pyogenes Aureus, Chronic Tubotympanic Purulent Otitis Media, Inflammation Of The Outer Ear And Ear Canal, Swimmer's Ear, Swimmer's Ear Due To Pseudomonas Aeruginosa, Swimmer's Ear Due To Staphylococcus Aureus.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Specific drug interaction studies have not been performed using ofloxacin ophthalmic or otic preparations. However, since systemic absorption may occur following topical application of ofloxacin to the eye or ear, the possibility of drug interactions such as those reported with systemic administration of some quinolone anti-infectives (e.g., interactions with theophylline, caffeine, oral anticoagulants, cyclosporine) should be considered.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
There are no adequate and controlled studies to date using ofloxacin 0.3% ophthalmic solution or ofloxacin 0.3% otic solution in pregnant women, and these preparations should be used during pregnancy only when potential benefits justify possible risks to the fetus.
Reproductive studies in rats and rabbits using oral ofloxacin dosages as high as 810 and 160 mg/kg daily (equivalent to 9000 and 1800 times the maximum recommended daily ophthalmic dosage, respectively) did not reveal evidence of teratogenicity. However, embryocidal effects were reported in rats and rabbits receiving such dosages. Decreased fetal body weight and retardation in the degree of ossification and minor skeletal variations, such as cervical ribs and shortened or absent 13th ribs, were reported in the rats; increased fetal mortality was reported in the rabbits. Perinatal and postnatal studies in rats given oral ofloxacin dosages up to 360 mg/kg daily (4000 times the maximum recommended daily ophthalmic dosage) revealed a decrease in food intake during gestation and an increase in food and water intake during lactation, but did not reveal evidence of adverse effects on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the offspring.
It is not known whether ofloxacin is distributed into milk following topical application to the eye or ear; however, ofloxacin is distributed into milk following oral administration.
Because of the potential for serious adverse effects of ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.